期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米在恶性血液病治疗中的应用进展 被引量：4

Application of Bortezomib in the Treatment of Malignant Hematonosis
原文传递
导出
摘要 目的:归纳硼替佐米在恶性血液病治疗中的应用进展。方法:对硼替佐米的结构性质、作用机制与其在恶性浆细胞病、非霍奇金淋巴瘤和白血病中的应用以及不良反应进行述评。结果与结论:蛋白酶体成为恶性血液病治疗中的重要靶点。硼替佐米在骨髓瘤的治疗中显示出独特优势,在白血病、恶性淋巴瘤等治疗中也取得了进展。以硼替佐米为核心的方案在治疗恶性血液病方面的疗效值得期待。 OBJECTIVE： To summarize the application and development of bortezomib in the treatment of malignant hematono- sis. METHODS： The structure, property and mechanism of bortezomib, application of it in malignant plasma cell dyscrasias, non-Hodgkin lymphoma and leukocythemia as well as ADR were all reviewed. RESULTS＆CONCLUSIONS： Proteasomes is consid- ered as a target in malignant hematonosis therapy. Bortezomib shows unique advantage in myeloma therapy and completes some achievements in leukocythemia and lymphoma therapy, etc. Therapeutic efficacy of bortezomib-based malignant hematonosis thera- py plan will have been worth the waiting.
作者 高力 张曦
机构地区 第三军医大学新桥医院血液科
出处 《中国药房》 CAS CSCD 2013年第38期3555-3558,共4页 China Pharmacy
基金 国家自然科学基金资助项目(No.81070388) 国家重点基础研究发展计划(973计划)资助课题子课题(No.2012CB518103)
关键词 硼替佐米 恶性血液病 进展 Bortezomib Malignant hematonosis Development
分类号 R973 [医药卫生—药品] R969.3 [医药卫生—药理学]
  • 相关文献

参考文献31

  • 1Mitchell BS.The proteasome-an emerging therapeutic target in cancer[J].N Engl J Med,2003,348(26):2 597.
  • 2Roccaro AM,Hideshima T,Richardson PG,et al.Bortezomib as an antitumor agent[J].Curr Pharm Biotechnol,2006,7(6):441.
  • 3Boccadoro M,Morgan G,Cavenagh J.Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy[J].Cancer Cell Int,2005,5(1):18.
  • 4Harousseau JL,Attal M,Avet-Loiseau H,et al.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01phaseⅢtrial[J].J Clin Oncol,2010,28(30):4 621.
  • 5Sonneveld P,Schmidt-Wolf IG,Van der Holt B,et al.Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phaseⅢHOVON-65/GMMG-HD4 trial[J].J Clin Oncol,2012,30(24):2 946.
  • 6Reeder CB,Reece DE,Kukreti V.Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma[J].Blood,2010,115(16):3 416.
  • 7Cavo M,Tacchetti P,Patriarca F,et al.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before,and consolidation therapy after,double autologous transplantation in newly diagnosed multiple myeloma:a radomised phase 3 study[J].Lancet,2010,376(9 758):2 075.
  • 8San Miguel JF,Schlag R,Khuageva NK,et al.VISTA Trial Investigators.Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma[J].N Engl J Med,2008,359(9):906.
  • 9Mateos MV,Richardson PG,Schlag R,et al.Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma:updated follow-up and impact of subsequent therapy in the phaseⅢVISTA trial[J].J Clin Oncol,2010,28(13):2 259.
  • 10San Miguel JF,Schlag R,Khuageva NK,et al.Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma[J].J Clin Oncol,2013,31(4):448.

同被引文献30

  • 1亢卉.硼替佐米在恶性血液病中的作用机制[J].中国新药与临床杂志,2006,25(6):459-462. 被引量：9
  • 2MEISTER S,SCHUBERT U,NEUBERT K,et al.Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition[J].Cancer Res,2007,67(4):1783-1792.
  • 3ROSINOL L,MONTOTO S,CIBEIRA MT,et al.Bortezomibinduced severe hepatitis in multiple myeloma:a case report[J].Arch Intern Med,2005,165(4):464-465.
  • 4PLASMATI R,PASTORELLI F,CAVO M,et al.Neuropathy in multiple myeloma treated with thalidomide:a prospective study[J].Neurology,2007,69(6):573-581.
  • 5RICHARDSON PG,XIE W,MITSIADES C,et al.Single-agent bortezomib in previously untreated multiple myeloma:efficacy,characterization of peripheral neuropathy,and molecular correlations with response and neuropathy[J].J Clin Oncol,2009,27(21):3518-3525.
  • 6MORAWSKA M,GRZASKO N,KOSTYRA M,et al.Therapyrelated peripheral neuropathy in multiple myeloma patients[J].Hematol Oncol,2015,33(4):113-119.
  • 7RICHARDSON PG,BARLOGIE B,BERENSON J,et al.A phase 2 study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348(26):2609-2617.
  • 8JAGANNATH S,BARLOGIE B,BERENSON J,et al.A phase2 study of two doses of bortezomib in relapsed or refractory myeloma[J].Br J Haematol,2004,127(2):165-172.
  • 9RICHARDSON PG,SONNEVELD P,SCHUSTER M,et al.Extended follow-up of a phase 3 trial in relapsed of the APEX trial[J].Blood,2007,110(10):3557-3560.
  • 10MOREAU P,PYLYPENKO H,GROSICKI S,et al.Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomized,phase 3,non inferiority study[J].Lancet Oncol,2011,12(5):431-440.

引证文献4

二级引证文献4

中国药房
2013年 第38期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部